Timing of sodium-glucose cotransporter 2 inhibitor initiation and post-discharge outcomes in acute heart failure with diabetes: A population-based cohort study

被引：1
|
作者：
Wu, Che-Yuan [1 ,2 ]
Shah, Baiju R. [3 ,4 ,5 ]
Sharma, Abhinav [6 ,7 ]
Sheng, Yiru [3 ]
Liu, Peter P. [8 ]
Kopp, Alexander [3 ]
Saskin, Refik [3 ]
Edwards, Jodi D. [8 ,9 ,10 ]
Swardfager, Walter [1 ,2 ,11 ]
机构：
[1] Univ Toronto, Dept Pharmacol & Toxicol, 1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada
[2] Sunnybrook Res Inst, Dr Sandra Black Ctr Brain Resilience & Recovery, Hurvitz Brain Sci Program, Toronto, ON, Canada
[3] ICES, Toronto, ON, Canada
[4] Sunnybrook Hlth Sci Ctr, Dept Med, Div Endocrinol, Toronto, ON, Canada
[5] Univ Toronto, Dept Med, Toronto, ON, Canada
[6] McGill Univ, Hlth Ctr, Div Cardiol, Montreal, PQ, Canada
[7] McGill Univ, Hlth Ctr, DREAM CV Lab, Montreal, PQ, Canada
[8] Univ Ottawa, Heart Inst, Ottawa, ON, Canada
[9] Univ Ottawa, Sch Epidemiol & Publ Hlth, Ottawa, ON, Canada
[10] ICES UOttawa, Ottawa, ON, Canada
[11] KITE Univ Hlth Network Toronto Rehabil Inst, Toronto, ON, Canada
来源：
EUROPEAN JOURNAL OF HEART FAILURE | 2025年 / 27卷 / 02期
基金：
加拿大健康研究院;
关键词：
Acute heart failure; Diabetes; SGLT2; inhibitor; Pharmacoepidemiology; IMPACT; RISK;
D O I：
10.1002/ejhf.3464
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Sodium-glucose cotransporter 2 (SGLT2) inhibitors in acute heart failure. image
引用
收藏
页码：307 / 316
页数：10
相关论文
共 50 条
  • [21] Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes A Population-Based Cohort Study
    Fralick, Michael
    Chen, Sarah K.
    Patorno, Elisabetta
    Kim, Seoyoung C.
    ANNALS OF INTERNAL MEDICINE, 2020, 172 (03) : 186 - +
  • [22] Haemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitor Treatment in Chronic Heart Failure Patients
    Nilsson, C. Noah
    Ersboll, Mads Kristian
    Gustafsson, Finn
    CARDIAC FAILURE REVIEW, 2024, 10
  • [23] Evaluation of Loop Diuretic Dosing Following Sodium-Glucose Cotransporter 2 Inhibitor Initiation in Patients With Heart Failure
    Trudeau, Brooke M.
    Allen, Larry A.
    Billups, Sarah J.
    Saseen, Joseph J.
    Pearson, Scott M.
    JOURNAL OF PHARMACY PRACTICE, 2023, 36 (06) : 1330 - 1335
  • [24] Cardiorenal outcomes and mortality after sodium-glucose cotransporter-2 inhibitor initiation in type 2 diabetes patients with percutaneous coronary intervention history
    Kim, Jin Hwa
    Lyu, Young Sang
    Kim, BongSeong
    Kim, Mee Kyung
    Kim, Sang Yong
    Baek, Ki-Hyun
    Song, Ki-Ho
    Han, Kyungdo
    Kwon, Hyuk-Sang
    DIABETES OBESITY & METABOLISM, 2024, 26 (07) : 2567 - 2577
  • [25] Sodium-glucose cotransporter 2 inhibitors and heart failure: the best timing for the right patient
    Severino, Paolo
    D'Amato, Andrea
    Prosperi, Silvia
    Costi, Bettina
    Angotti, Danilo
    Birtolo, Lucia Ilaria
    Chimenti, Cristina
    Lavalle, Carlo
    Maestrini, Viviana
    Mancone, Massimo
    Fedele, Francesco
    HEART FAILURE REVIEWS, 2023, 28 (03) : 709 - 721
  • [26] Evaluation of sodium-glucose cotransporter 2 inhibitors for renal prognosis and mortality in diabetes patients with heart failure on diuretics
    Weng, Yi-Fang
    Chen, Chung-Yu
    Hwang, Shang-Jyh
    Huang, Yaw-Bin
    KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2023, 39 (04) : 416 - 425
  • [27] Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure
    Kolwelter, Julie
    Bosch, Agnes
    Jung, Susanne
    Stabel, Lena
    Kannenkeril, Dennis
    Ott, Christian
    Bramlage, Peter
    Schiffer, Mario
    Achenbach, Stephan
    Schmieder, Roland E.
    ESC HEART FAILURE, 2022, 8 (06): : 5327 - 5337
  • [28] Therapeutic effects on the development of heart failure with preserved ejection fraction by the sodium-glucose cotransporter 2 inhibitor dapagliflozin in type 2 diabetes
    Feng, Bin
    Yu, Peiran
    Yu, Hao
    Qian, Buyun
    Li, Yuan
    Sun, Kangyun
    Shi, Bimin
    Zhang, Nannan
    Xu, Guidong
    DIABETOLOGY & METABOLIC SYNDROME, 2023, 15 (01)
  • [29] Sodium-glucose cotransporter 2 inhibitor effects on heart failure hospitalization and cardiac function: systematic review
    Rasalam, Roy
    Atherton, John J.
    Deed, Gary
    Molloy-Bland, Michael
    Cohen, Neale
    Sindone, Andrew
    ESC HEART FAILURE, 2021, 8 (05): : 4093 - 4118
  • [30] Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure
    Kolwelter, Julie
    Bosch, Agnes
    Jung, Susanne
    Stabel, Lena
    Kannenkeril, Dennis
    Ott, Christian
    Bramlage, Peter
    Schiffer, Mario
    Achenbach, Stephan
    Schmieder, Roland E.
    ESC HEART FAILURE, 2021, 8 (06): : 5327 - 5337
12345